



PEPTECH
LIMITED

Peptech Limited
ABN 98 002 951 877

19-25 Khartoum Rd
Macquarie Park NSW 2113 Australia

Locked Bag 2053
North Ryde NSW 1670 Australia

Telephone +61 2 9870 8788
Facsimile +61 2 9870 8786

25 September 2006

ASX / MEDIA ANNOUNCEMENT

Suprelorin12[®] Registered in Australia

Peptech Animal Health Pty Limited (PAH), a wholly-owned subsidiary of Australian biotechnology company Peptech Limited (ASX:PTD), today announced it had received registration approval for its advanced canine contraceptive, Suprelorin12[®].

Suprelorin12[®], the next generation of PAH's Suprelorin[®], provides a safe and effective fertility-control alternative to surgical castration in male canines and is anticipated to be launched in Australia in the coming months.

PAH's latest product, Suprelorin12[®] boasts a 12 month duration of action, extending the benefits of the original Suprelorin[®], which is active for six months.

Peptech Animal Health General Manager Dr Paul Schober said Suprelorin[®], launched into the Australian and New Zealand market two years ago, had been progressively accepted by the trans-Tasman veterinary market.

"Suprelorin[®] sales in Australia increased by 18% over the last six months compared with the previous six months and by over 70% from the corresponding period last year," he said.

"We are pleased to see the market is continuing to realise the value and benefits of this product and we are confident that the increased convenience provided by the 12 month product will generate greater market penetration".

"Castration isn't always the best option for male dogs for a variety of reasons, and in some regions, particularly in Europe, it has become an increasingly unpopular, if not illegal, practice" Dr Schober said.

Suprelorin[®], routinely administered by vets as an implant under the animal's skin, provides vets and dog owners with a more humane, but equally efficacious and cost-effective, alternative.

Peptech Animal Health Marketing and Technical Services Manager Dr Katie Yeates said the Suprelorin12[®] solution offered dog owners the convenience and surety of fertility control with a treatment which can be administered with the animal's annual vaccination.

PAH is currently pursuing registration applications with regulatory authorities in both the US and Europe. Suprelorin[®] is expected to generate revenue from the lucrative European market during 2007.

ENDS

Further information:

Dr Paul Schober
General Manager
Peptech Animal Health Pty Limited
Phone: 02 9870 8788

Released by:

Ms Jodie Leckenby
Consultant
Phillips Group
Mobile: 0403 783 932

About Peptech:

Peptech Limited focuses on the research and development of peptides and proteins in the areas of human pharmaceuticals and animal health. The company is positioned to become a globally recognised leader in biopharmaceutical development.

For further information: www.peptech.com

About Suprelorin[®] and Suprelorin12[®]

The active agent in both products is a synthetic analogue of a naturally occurring hormone (LHRH). When this analogue is given over a sustained period of time the chemical message to product steroid hormones from the pituitary gland to the gonads is impaired. The drug delivery platform for Suprelorin[®] and Suprelorin12[®] - a subcutaneous, slow-release, lecithin-based, biocompatible implant - is unique in the market and has wide potential applications. Peptech is a world leader in this type of slow-release implantable technology.

Trials of up to five consecutive treatments over three years of Suprelorin[®] have shown that fertility returns when treatment is stopped, making the treatment reversible, which is a major bonus for breeders.

Because they halt the production of testosterone, Suprelorin[®] and Suprelorin12[®] achieve reversible sterilisation as well as similar behavioural improvements seen with castration. The implants have also been shown to be effective in treating benign prostrate hyperplasia, an enlargement of the prostate gland commonly seen in older entire dogs that can cause numerous clinical signs varying in severity.

Suprelorin[®] (as a 2.3x6mm cylindrical dose) and Suprelorin12[®] (2.3x12mm) are inserted between the dog's shoulders. The disposable implanter is no larger than that used to implant microchips in dogs and is a highly cost-effective way to deliver the drug. No anaesthetic is required and there is none of the discomfort, recovery or potential risks that would be associated with surgery.

Both Suprelorin[®] and Suprelorin12[®] have potential beyond the reversible sterilisation of male dogs, to improve the health of many species of animals on a number of fronts.

Recent studies show that both products are also effective in treating incontinence in spayed bitches. This gives dog owners a convenient long-term treatment option over the current therapies that not only require frequent medicating but can be associated with dangerous side-effects.

Suprelorin[®] and Suprelorin12[®] are currently being used in wildlife parks and zoos for population control on a number of different species including lions, cheetahs, monkeys, dolphins, seals and other mammals.

Patent applications are being expanded to cover repeat usage, use in females, use for other indications and in other animal species.

Further information is available on Peptech's website: www.peptech.com